This inventor holds 203 USPTO granted patents and 61 published patent applications, plus 9 CIPO patents and 28 EPO patents, primarily in Gene Modulation (CPC class C12N15-113). Top assignees: Isis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Regulus Therapeutics Inc.. Active years: 1996-2026.
Inventors with similar research interests:
Location History:
- San Diego, CA (US) (2021)
- Carlsbad, CA (US) (1996 - 2023)
Company Filing History:
134 out of 1,035 
34 out of 288 
27 out of 63 
Years Active: 1996-2026
Areas of Expertise:
Title: C Frank Bennett: Pioneering Innovator and Accomplished Inventor
Introduction:
In the world of innovations and patents, few individuals can match the remarkable contributions and expertise of C Frank Bennett. Hailing from Carlsbad, CA in the United States, Bennett has made a profound impact through his inventive mind and extensive knowledge. With an impressive repertoire of 146 patents to his name, Bennett's groundbreaking work stands as a testament to his unwavering commitment to advancing scientific understanding and improving lives.
Latest Patents:
Bennett's latest patents demonstrate his proficiency in pioneering areas of research. His patent titled "Compositions and Methods for Modulation of SMN2 Splicing in a Subject" showcases his novel approach to improving the splicing of SMN2 mRNA, a critical element in addressing spinal muscular atrophy. By developing compounds, compositions, and methods to modulate this process, Bennett's work holds the potential to significantly impact the treatment of this debilitating condition.
Another recent patent is his invention related to "Compositions and Methods for Modulation of Protein Aggregation." This innovative approach involves the administration of modified oligonucleotides to combat protein aggregation within cells. By reducing the size or amount of protein aggregates, potentially disrupting mRNP granules, Bennett's research may open new avenues in the field of protein-related disorders.
Career Highlights:
During his illustrious career, Bennett has achieved numerous milestones. His valuable contributions were recognized during his tenure at Isis Pharmaceuticals, Inc., a renowned biopharmaceutical company. His work at Isis Pharmaceuticals, Inc. exemplifies his dedication to developing groundbreaking therapeutics and refining methodologies in the field of RNA-based therapeutics.
Collaborations:
Collaboration is often the driving force behind transformative innovations. Bennett has had the privilege of working alongside esteemed colleagues during his career. One such collaboration was with Susan M Freier, who has made significant contributions to the development of antisense oligonucleotide therapies. Together, their collective expertise and shared vision created a synergy that paved the way for cutting-edge advancements.
Another notable collaboration for Bennett was with Lex M Cowsert, a prominent figure in the field of pharmaceutical research. Their joint efforts have not only propelled the understanding of nucleic acid therapeutics but have also paved the way for remarkable breakthroughs in combating various diseases.
Conclusion:
C Frank Bennett's journey as an inventor and innovator has been marked by groundbreaking advancements in the areas of RNA therapeutics, splicing modulation, and protein aggregation. With an impressive portfolio of 146 patents and collaborations with esteemed professionals like Susan M Freier and Lex M Cowsert, Bennett's work continues to shape the landscape of pharmaceutical research. His dedication, passion, and intellect have undoubtedly made a lasting impact, improving the lives of countless individuals worldwide.